Eliciting dose is associated with tolerance development in peanut and cow’s milk allergic children

• Letter to the Editor
• Open Access

Clinical and Translational Allergy

• C. Nitsche, 
• C. D. Westerlaken-van Ginkel, 
• B. J. Kollen, 
• A. B. Sprikkelman, 
• G. H. Koppelman & 
• A. E. J. Dubois 

Clinical and Translational Allergy volume 9, Article number: 58 (2019) 

• details

Abstract

Background

Kaplan-Meier survival curve in peanut, cow’s milk and hen’s egg allergic children

Tolerance development rates differ between food allergies. Almost all previous studies have not used the gold standard method, the double-blind, placebo-controlled food challenge (DBPCFC), which may affect the reported prevalence rates. Little is known about the association of the eliciting dose (ED) obtained during the initial DBPCFC with later tolerance development.

Helsinki by nature: The Nature Step to Respiratory Health

• Review
• Open Access

Clinical and Translational Allergy

• Tari Haahtela, 
• Leena von Hertzen, 
• […]
• Nils E. Billo 

Clinical and Translational Allergy volume 9, Article number: 57 (2019) 

Abstract

Background

Several non-communicable diseases have been suggested
to share the same underlying risk factors such as microbial imbalance,
 long-term immune dysfunction and low-grade inflammation

The Nature Step to Respiratory Health was the overarching theme of the 12th General Meeting of the Global Alliance against Chronic Respiratory Diseases (GARD) in Helsinki, August 2018. New approaches are needed to improve respiratory health and reduce premature mortality of chronic diseases by 30% till 2030 (UN Sustainable Development Goals, SDGs). Planetary health is defined as the health of human civilization and the state of the natural systems on which it depends. Planetary health and human health are interconnected, and both need to be considered by individuals and governments while addressing several SDGs.

The association between caesarean section and childhood asthma: an updated systematic review and meta-analysis

Allergy, Asthma & Clinical Immunology

Behzad Darabi, 

Shoboo Rahmati, 

Mohammad Reza HafeziAhmadi, 

Gholamreza Badfar & 

Milad Azami 

Allergy, Asthma & Clinical Immunology volume 15, Article number: 62 (2019) 

• details

Abstract

Background

Investigating the association between caesarean section (SC) and childhood asthma has shown contradictory results in different studies. The present study was conducted to determine the association between SC and childhood asthma.

Material and method

The present study was conducted based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. All the steps of the study were conducted independently by two reviewers from the inception until February 1, 2019.

The safety and tolerability profile of bilastine for chronic urticaria in children

• Review
• Open Access
• Clinical and Translational Allergy

• Nikolaos G. Papadopoulos & 
• Torsten Zuberbier 

Clinical and Translational Allergy volume 9, Article number: 55 (2019) 

Abstract

Background

Urticaria is a condition defined by the development of wheals, angioedema or both. It is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks). Chronic urticaria is less frequent than acute one in children, but it represents a debilitating condition, always needing treatment. Symptoms affect child’s daily activities and disturb sleeping patterns, causing emotional distress and negatively influencing learning and cognition.

Clinical Reflections®: Reflecting on Errors and Missed Opportunities in Chronic Urticaria

FORMAT

Roundtable

TIME TO COMPLETE

45 minutes

RELEASED

February 1, 2019

EXPIRES

January 31, 2020

Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.

START ACTIVITY

MAXIMUM CREDITS

0.75 / AMA PRA Category 1 Credit(s)TM

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

Key Points

Question  Does the oral Janus kinase 1 selective inhibitor abrocitinib improve atopic dermatitis signs and symptoms in adults with moderate to severe atopic dermatitis at doses that are well tolerated?

Findings  In this randomized, double-blinded, phase 2b clinical trial including 267 participants, the proportion of patients achieving substantial improvement from baseline was significantly greater for those receiving 200 mg and 100 mg of abrocitinib compared with placebo. Dose-related decreases in platelet count were observed for all doses greater than 10 mg, but platelet values trended upward toward baseline after the maximum decrease at week 4 and despite ongoing treatment with abrocitinib; most adverse events were mild and considered unrelated to treatment.

SABA overuse: Understanding the reasons for poor asthma control

Prof. John Haughney

Speaker

Clinical Director of the NHS Clinical Research Facilities, Glasgow

Dr John Haughney is a Clinical Director in clinical R&D and the Clinical Research Facilities in NHS Greater Glasgow & Clyde, Scotland, a part-time general practitioner and hospital respiratory specialist. He holds Fellowships from both the Royal College of General Practitioners and the Royal College of Physicians of Edinburgh.

John is a past-president of the International Primary Care Respiratory Group and a former Chair of the GPIAG (PCRS (UK)). He holds honorary academic positions at both the University of Glasgow and the University of Aberdeen and travels extensively teaching and learning about airways disease.

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

• Research article
• Open Access
• Open Peer Review

BMC Pulmonary Medicine

• Takanori Numata, 
• Katsutoshi Nakayama, 
• Hirofumi Utsumi, 
• Kenji Kobayashi, 
• Haruhiko Yanagisawa, 
• Mitsuo Hashimoto, 
• Shunsuke Minagawa, 
• Takeo Ishikawa, 
• Hiromichi Hara, 
• Jun Araya & 
• Kazuyoshi Kuwano 

BMC Pulmonary Medicine volume 19, Article number: 176 (2019) | 

Abstract

Background

Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance therapy. However, the predictive factors of the response to mepolizumab other than blood eosinophil count are unclear in clinical practice.